Deutsch English Français

Contact

EP2396005

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2396005

EP2396005 - SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA [Right-click to bookmark this link]
Former [2011/51]	SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA
	[2012/07]
Status	Examination is in progress Status updated on 25.11.2016 Database last updated on 07.10.2024
Most recent event Tooltip	01.03.2024	New entry: Renewal fee paid
Applicant(s)	For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE
	[N/P]
Former [2011/51]	For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE
Inventor(s)	01 / EICKELMANN, Peter Boehringer Ingelheim GmbH CD Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	02 / MARK, Michael Boehringer Ingelheim GmbH CD Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	03 / SEMAN, Leo John Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road Ridgefield, CT 06877 / US
	04 / THOMAS, Leo Boehringer Ingelheim GmbH CD Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	05 / BROEDL, Uli Boehringer Ingelheim GmbH CD Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	06 / GREMPLER, Rolf Boehringer Ingelheim GmbH CD Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
	[2011/51]
Representative(s)	Lutze, Oliver, et al Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE
	[N/P]
Former [2012/40]	Simon, Elke Anna Maria, et al Boehringer Ingelheim GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE
Former [2011/51]	Hammann, Heinz Boehringer Ingelheim GmbH CD Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE
Application number, filing date	10703287.2	11.02.2010
	WO2010EP51734
Priority number, date	US20090152318P	13.02.2009 Original published format: US 152318 P
	[2011/51]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010092123
	Date:	19.08.2010
	Language:	EN
	[2010/33]
	Type:	A1 Application with search report
	No.:	EP2396005
	Date:	21.12.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 19.08.2010 takes the place of the publication of the European patent application.
	[2011/51]
Search report(s)	International search report - published on:	EP	19.08.2010
Classification	IPC:	A61K31/7034, A61P3/10, A61P3/04, A61P3/06	[2011/51]
	CPC:	A61K31/7048 (EP,US); A61K31/7034 (KR,US); A61K47/26 (EP); A61K9/0019 (EP,KR); A61K9/0031 (KR); A61K9/02 (KR); (+) A61K9/2018 (EP); A61K9/2027 (EP); A61K9/4866 (EP); A61P1/18 (EP); A61P11/00 (EP); A61P13/12 (EP); A61P19/06 (EP); A61P25/00 (EP); A61P27/02 (EP); A61P27/12 (EP); A61P3/00 (EP); A61P3/04 (EP); A61P3/06 (EP); A61P3/08 (EP); A61P3/10 (EP); A61P37/06 (EP); A61P43/00 (EP); A61P5/50 (EP); A61P9/00 (EP); A61P9/04 (EP); A61P9/06 (EP); A61P9/08 (EP); A61P9/10 (EP) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2011/51]
Extension states	BA	13.09.2011
	RS	13.09.2011
Title	German:	SGLT-2-HEMMER ZUR BEHANDLUNG VON DIABETES MELLITUS TYP 1, DIABETES MELLITUS TYP 2, BEEINTRÄCHTIGER GLUKOSETOLERANZ ODER HYPERGLYKÄMIE	[2011/51]
	English:	SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA	[2012/07]
	French:	INHIBITEUR SGLT-2 POUR LE TRAITEMENT DU DIABÈTE SUCRÉ DE TYPE 1, DU DIABÈTE SUCRÉ DE TYPE 2, D'UNE INTOLÉRANCE AU GLUCOSE OU D'UNE HYPERGLYCÉMIE	[2011/51]
	Former [2011/51]	SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA
Entry into regional phase	13.09.2011	National basic fee paid
	13.09.2011	Designation fee(s) paid
	13.09.2011	Examination fee paid
Examination procedure	13.09.2011	Examination requested [2011/51]
	05.04.2012	Amendment by applicant (claims and/or description)
	08.02.2016	Despatch of a communication from the examining division (Time limit: M06)
	22.11.2016	Reply to a communication from the examining division
	06.09.2019	Despatch of a communication from the examining division (Time limit: M06)
	31.08.2020	Reply to a communication from the examining division
	02.06.2022	Despatch of a communication from the examining division (Time limit: M06)
	11.01.2023	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	20.03.2023	Reply to a communication from the examining division
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.02.2016
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	20.03.2023	Request for further processing filed
	20.03.2023	Full payment received (date of receipt of payment) Request granted
	29.03.2023	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	31.08.2020	Request for further processing filed
	31.08.2020	Full payment received (date of receipt of payment) Request granted
	14.09.2020	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	22.11.2016	Request for further processing filed
	22.11.2016	Full payment received (date of receipt of payment) Request granted
	05.12.2016	Decision despatched
Fees paid	Renewal fee
	29.02.2012	Renewal fee patent year 03
	28.02.2013	Renewal fee patent year 04
	28.02.2014	Renewal fee patent year 05
	02.03.2015	Renewal fee patent year 06
	29.02.2016	Renewal fee patent year 07
	28.02.2017	Renewal fee patent year 08
	28.02.2018	Renewal fee patent year 09
	28.02.2019	Renewal fee patent year 10
	02.03.2020	Renewal fee patent year 11
	01.03.2021	Renewal fee patent year 12
	28.02.2022	Renewal fee patent year 13
	28.02.2023	Renewal fee patent year 14
	29.02.2024	Renewal fee patent year 15
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XD]WO2006064033 (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-15 * paragraph [0027] * * paragraph [0175] * * paragraph [0178] *;
		[XD]WO2006117359 (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-15 * claim - * * paragraph [0017] - paragraph [0019] *;
		[X]WO2007014894 (BOEHRINGER INGELHEIM INT [DE], et al) [X] 1-15 * paragraph [0176] * * paragraph [0332] *;
		[XD]WO2007093610 (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-15 * paragraph [0209] * * paragraph [0206] * * paragraph [0015] * * paragraph [0322] * * paragraph [0363] *;
		[XD]WO2008055870 (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-15 * claims 10-14 * * example 7 * * page 63, line 20 * * page 60 - line 16 * * page 4, line 23 - line 29 * * page 59, line 7 * * page 60, line 11 *;
		[XP]WO2009022007 (BOEHRINGER INGELHEIM INT [DE], et al) [XP] 1-15* claim - *
	Examination	WO2005092877
		WO2008055940
	by applicant	WO0127128
		WO03099836
		WO2005092877
		WO2006034489
		WO2006064033
		WO2006117359
		WO2006117360
		WO2006120208
		WO2007025943
		WO2007028814
		WO2007031548
		WO2007093610
		WO2007128749
		WO2008020011
		WO2008049923
		WO2008055870
		WO2008055940
		- FORD ES ET AL., JAMA, (2002), vol. 287, pages 356 - 9
		- KATSUKI A ET AL., DIABETES CARE, (2001), vol. 24, pages 362 - 5
		- MATTHEWS ET AL., DIABETOLOGIA, (1985), vol. 28, pages 412 - 19
		- FORST ET AL., DIABETES, (2003), vol. 52, no. 1, page A459
		- GALVIN P ET AL., DIABET MED, (1992), vol. 9, pages 921 - 8
		- STUMVOLL ET AL., EUR J CLIN INVEST, (2001), vol. 31, pages 380 - 81
		- J. B. MEIGS ET AL., DIABETES, (2003), vol. 52, pages 1475 - 1484
		- The Prevention or Delay of Type 2 Diabetes, AMERICAN DIABETES ASSOCIATION, (2002), vol. 25, pages 742 - 749
		- LAAKSONEN DE ET AL., AM J EPIDEMIOL, (2002), vol. 156, pages 1070 - 7
		- JAMA: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, (2001), vol. 285, pages 2486 - 2497
		- LAAKSONEN DE ET AL., AM J EPIDEMIOL., (2002), vol. 156, pages 1070 - 7

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p